Participants 620 795 5
patients with lung cancer who had been treated with myelosuppressive chemotherapy and then with subcutaneous rhG-CSF (lenograstim, 2 micrograms per kg of body weight per day).
Participants 796 891 7
Twelve patients were randomly assigned to four groups with different rhG-CSF therapy schedules.
